Selected research
Industry Research
Assisted Reproductive Technologies Medications Industry Research Report 2026
Market perspective
The global Assisted Reproductive Technologies Medications market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Assisted Reproductive Technologies Medications market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Assisted Reproductive Technologies Medications market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Assisted Reproductive Technologies Medications market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Assisted Reproductive Technologies Medications include Zhejiang Xianju, Merck Serono, Livzon Pharmaceutical, Changchun GeneScience, Hybio Pharmaceutical, Solvay, Organon, Ipsen and Ferring and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Assisted Reproductive Technologies Medications market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Assisted Reproductive Technologies Medications.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Assisted Reproductive Technologies Medications Market by Company
Zhejiang Xianju
Merck Serono
Livzon Pharmaceutical
Changchun GeneScience
Hybio Pharmaceutical
Solvay
Organon
Ipsen
Ferring
Besins
Assisted Reproductive Technologies Medications Segment by Type
Ovulation Stimulation Drugs
Luteal Support Medications
Down-Regulation Drugs
Ovulation Inducing Drugs
Assisted Reproductive Technologies Medications Segment by Application
Specialty & Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Assisted Reproductive Technologies Medications Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Assisted Reproductive Technologies Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Assisted Reproductive Technologies Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Assisted Reproductive Technologies Medications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Assisted Reproductive Technologies Medications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ovulation Stimulation Drugs
- Luteal Support Medications
- Down-Regulation Drugs
- Ovulation Inducing Drugs
Applications
- Specialty & Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
Companies covered
- Zhejiang Xianju
- Merck Serono
- Livzon Pharmaceutical
- Changchun GeneScience
- Hybio Pharmaceutical
- Solvay
- Organon
- Ipsen
- Ferring
- Besins
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Assisted Reproductive Technologies Medications by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Ovulation Stimulation Drugs
- 2.2.3 Luteal Support Medications
- 2.2.4 Down-Regulation Drugs
- 2.2.5 Ovulation Inducing Drugs
- 2.3 Assisted Reproductive Technologies Medications by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Specialty & Retail Pharmacy
- 2.3.3 Hospital Pharmacy
- 2.3.4 Online Pharmacy
- 2.4 Assumptions and Limitations
3 Assisted Reproductive Technologies Medications Breakdown Data by Type
- 3.1 Global Assisted Reproductive Technologies Medications Historic Market Size by Type (2021-2026)
- 3.2 Global Assisted Reproductive Technologies Medications Forecasted Market Size by Type (2027-2032)
4 Assisted Reproductive Technologies Medications Breakdown Data by Application
- 4.1 Global Assisted Reproductive Technologies Medications Historic Market Size by Application (2021-2026)
- 4.2 Global Assisted Reproductive Technologies Medications Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Assisted Reproductive Technologies Medications Market Perspective (2021-2032)
- 5.2 Global Assisted Reproductive Technologies Medications Growth Trends by Region
- 5.2.1 Global Assisted Reproductive Technologies Medications Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Assisted Reproductive Technologies Medications Historic Market Size by Region (2021-2026)
- 5.2.3 Assisted Reproductive Technologies Medications Forecasted Market Size by Region (2027-2032)
- 5.3 Assisted Reproductive Technologies Medications Market Dynamics
- 5.3.1 Assisted Reproductive Technologies Medications Industry Trends
- 5.3.2 Assisted Reproductive Technologies Medications Market Drivers
- 5.3.3 Assisted Reproductive Technologies Medications Market Challenges
- 5.3.4 Assisted Reproductive Technologies Medications Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Assisted Reproductive Technologies Medications Players by Revenue
- 6.1.1 Global Top Assisted Reproductive Technologies Medications Players by Revenue (2021-2026)
- 6.1.2 Global Assisted Reproductive Technologies Medications Revenue Market Share by Players (2021-2026)
- 6.2 Global Assisted Reproductive Technologies Medications Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Assisted Reproductive Technologies Medications Head Office and Area Served
- 6.4 Global Assisted Reproductive Technologies Medications Players, Product Type & Application
- 6.5 Global Assisted Reproductive Technologies Medications Manufacturers Established Date
- 6.6 Global Assisted Reproductive Technologies Medications Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Assisted Reproductive Technologies Medications Market Size (2021-2032)
- 7.2 North America Assisted Reproductive Technologies Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Assisted Reproductive Technologies Medications Market Size by Country (2021-2026)
- 7.4 North America Assisted Reproductive Technologies Medications Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Assisted Reproductive Technologies Medications Market Size (2021-2032)
- 8.2 Europe Assisted Reproductive Technologies Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Assisted Reproductive Technologies Medications Market Size by Country (2021-2026)
- 8.4 Europe Assisted Reproductive Technologies Medications Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Assisted Reproductive Technologies Medications Market Size (2021-2032)
- 9.2 Asia-Pacific Assisted Reproductive Technologies Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Assisted Reproductive Technologies Medications Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Assisted Reproductive Technologies Medications Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Assisted Reproductive Technologies Medications Market Size (2021-2032)
- 10.2 South America Assisted Reproductive Technologies Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Assisted Reproductive Technologies Medications Market Size by Country (2021-2026)
- 10.4 South America Assisted Reproductive Technologies Medications Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Assisted Reproductive Technologies Medications Market Size (2021-2032)
- 11.2 Middle East & Africa Assisted Reproductive Technologies Medications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Assisted Reproductive Technologies Medications Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Assisted Reproductive Technologies Medications Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Zhejiang Xianju
- 12.1.1 Zhejiang Xianju Company Information
- 12.1.2 Zhejiang Xianju Business Overview
- 12.1.3 Zhejiang Xianju Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.1.4 Zhejiang Xianju Assisted Reproductive Technologies Medications Product Portfolio
- 12.1.5 Zhejiang Xianju Recent Developments
- 12.2 Merck Serono
- 12.2.1 Merck Serono Company Information
- 12.2.2 Merck Serono Business Overview
- 12.2.3 Merck Serono Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.2.4 Merck Serono Assisted Reproductive Technologies Medications Product Portfolio
- 12.2.5 Merck Serono Recent Developments
- 12.3 Livzon Pharmaceutical
- 12.3.1 Livzon Pharmaceutical Company Information
- 12.3.2 Livzon Pharmaceutical Business Overview
- 12.3.3 Livzon Pharmaceutical Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.3.4 Livzon Pharmaceutical Assisted Reproductive Technologies Medications Product Portfolio
- 12.3.5 Livzon Pharmaceutical Recent Developments
- 12.4 Changchun GeneScience
- 12.4.1 Changchun GeneScience Company Information
- 12.4.2 Changchun GeneScience Business Overview
- 12.4.3 Changchun GeneScience Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.4.4 Changchun GeneScience Assisted Reproductive Technologies Medications Product Portfolio
- 12.4.5 Changchun GeneScience Recent Developments
- 12.5 Hybio Pharmaceutical
- 12.5.1 Hybio Pharmaceutical Company Information
- 12.5.2 Hybio Pharmaceutical Business Overview
- 12.5.3 Hybio Pharmaceutical Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.5.4 Hybio Pharmaceutical Assisted Reproductive Technologies Medications Product Portfolio
- 12.5.5 Hybio Pharmaceutical Recent Developments
- 12.6 Solvay
- 12.6.1 Solvay Company Information
- 12.6.2 Solvay Business Overview
- 12.6.3 Solvay Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.6.4 Solvay Assisted Reproductive Technologies Medications Product Portfolio
- 12.6.5 Solvay Recent Developments
- 12.7 Organon
- 12.7.1 Organon Company Information
- 12.7.2 Organon Business Overview
- 12.7.3 Organon Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.7.4 Organon Assisted Reproductive Technologies Medications Product Portfolio
- 12.7.5 Organon Recent Developments
- 12.8 Ipsen
- 12.8.1 Ipsen Company Information
- 12.8.2 Ipsen Business Overview
- 12.8.3 Ipsen Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.8.4 Ipsen Assisted Reproductive Technologies Medications Product Portfolio
- 12.8.5 Ipsen Recent Developments
- 12.9 Ferring
- 12.9.1 Ferring Company Information
- 12.9.2 Ferring Business Overview
- 12.9.3 Ferring Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.9.4 Ferring Assisted Reproductive Technologies Medications Product Portfolio
- 12.9.5 Ferring Recent Developments
- 12.10 Besins
- 12.10.1 Besins Company Information
- 12.10.2 Besins Business Overview
- 12.10.3 Besins Revenue in Assisted Reproductive Technologies Medications Business (2021-2026)
- 12.10.4 Besins Assisted Reproductive Technologies Medications Product Portfolio
- 12.10.5 Besins Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst